What is the possibility of achieving Treatment-Free Remission (TFR) in the future? What criteria (depth and duration...

Treatment-Free Remission (TFR) in CML: Possibility and Criteria

Great question—this is an increasingly important goal for many CML patients. Let me break down what the evidence shows about TFR possibility and the specific criteria you'd need to meet.

Understanding TFR: Is It Possible for You?

The short answer: Yes, TFR is achievable for selected CML patients, but it requires meeting very specific criteria and close monitoring.

According to the NCCN Guidelines for CML, discontinuation of TKI therapy (which is what TFR means) "appears to be safe in select patients with CML." However, this is not for everyone—your care team will need to carefully evaluate whether you're a candidate.

Key Point About TFR Goals

The NCCN Guidelines emphasize that treatment goals have evolved. Historically, the main goal was long-term survival. Now, for patients interested in TFR, the treatment goal shifts earlier in therapy. This is important because it changes which response milestones your doctor will target.

---

Specific Criteria You Must Meet for TFR

The NCCN Guidelines outline strict eligibility criteria for TFR consideration. Here are the requirements:

1) Disease Characteristics (At Diagnosis)

• Chronic phase CML only — no prior history of accelerated phase (AP-CML) or blast phase (BP-CML)
• If you've already progressed to AP or BP, TFR is not an option

2) Duration of TKI Therapy

• Minimum 3 years on approved TKI therapy before you can even consider stopping
• This is a hard requirement—shorter durations have higher relapse risk

3) Molecular Response Depth — The Critical Requirement

This is where the "depth and duration" you asked about comes in:

You must achieve and maintain:

• Deep Molecular Response (DMR) at MR4.0 level or deeper
  • MR4.0 = BCR::ABL1 ≤0.01% (International Scale)
  • MR4.5 = BCR::ABL1 ≤0.0032% (even deeper)

Duration requirement:

• Stable DMR (MR4.0) for ≥2 years, documented on at least 4 separate tests performed at least 3 months apart

This means you need consistent, sustained deep response—not just one good test result.

4) Access to Sensitive Testing

• You must have access to a reliable qPCR test with sensitivity of at least MR4.5 (BCR::ABL1 ≤0.0032%)
• Results must be available within 2 weeks
• This is essential because you'll need frequent monitoring after stopping therapy

5) Informed Consent & Specialist Consultation

• Consultation with a CML specialist is required before attempting TFR
• You must understand and agree to the potential risks, including:
  • TKI withdrawal syndrome (flu-like symptoms, joint pain, other effects)
  • Risk of relapse if BCR::ABL1 rises
  • Need for intensive monitoring

---

What "Optimal Response" Means for TFR

Here's an important distinction from the NCCN Guidelines:

For patients whose goal is long-term survival:

• Target milestone = Complete Cytogenetic Response (CCyR) or ≤1% BCR::ABL1 by 12 months

For patients whose goal is TFR:

• Target milestone = Major Molecular Response (MMR) or ≤0.1% BCR::ABL1 by 12 months
• This is because achieving MMR early is associated with "a very low probability of subsequent loss of response and a high likelihood of achieving a subsequent DMR"

The bottom line: If TFR is your goal, your doctor should be targeting deeper molecular responses from the start of therapy.

---

Monitoring Requirements If You Attempt TFR

If you meet all criteria and decide to try TFR, here's what monitoring looks like:

After stopping TKI:

• Months 1-6: Monthly BCR::ABL1 testing (qPCR IS)
• Months 7-12: Bimonthly testing
• After 12 months: Quarterly testing (indefinitely)

If BCR::ABL1 rises above 0.1% (loss of MMR):

• Restart TKI therapy within 4 weeks
• Resume monthly monitoring until MMR is re-established
• Then return to every 3 months indefinitely

Important safety note: The NCCN Guidelines state that "prompt resumption of TKI within 4 weeks of a loss of MMR" is recommended. Most patients who restart therapy regain their response.

---

What Factors Predict Success or Relapse?

The NCCN Guidelines identify several factors that affect your likelihood of maintaining TFR:

Factors associated with higher relapse risk:

• Female gender
• Higher Sokal risk score at diagnosis
• Lower natural killer (NK) cell counts
• Shorter duration of TKI therapy before discontinuation
• Shorter duration of DMR before stopping

Positive predictor:

• Duration of TKI therapy before discontinuation was the most significant factor associated with maintaining MMR at 36 months after stopping in the EURO-SKI study

---

Real-World Outcomes

According to NCCN Guidelines data:

• Approximately 40-50% of carefully selected patients maintain MMR after TKI discontinuation
• Most patients who lose MMR regain it quickly when restarting therapy
• Relapse is usually detected early through frequent monitoring, before it becomes clinically significant

---

Questions to Ask Your CML Specialist About TFR

Based on this information, here are specific questions to discuss with your care team:

1. "Based on my current BCR::ABL1 level and response trajectory, do you think TFR is a realistic goal for me?"

2. "If TFR is possible, what molecular response level should we target in the next 12 months—MMR (≤0.1%) or deeper?"

3. "What is my Sokal risk score, and how does that affect my likelihood of successful TFR?"

4. "Do you have access to qPCR testing with MR4.5 sensitivity, and can results be available within 2 weeks?"

5. "If I achieve DMR for 2 years, would you be willing to discuss TFR, and do you have experience managing patients in TFR?"

6. "What would TKI withdrawal syndrome look like for me, and how would we manage it?"

7. "If my BCR::ABL1 rises during TFR, how quickly could I restart therapy, and what's the likelihood I'd regain my response?"

---

Summary: Your TFR Pathway

| Requirement | What You Need | |---|---| | Disease status | Chronic phase, no prior AP/BP | | TKI duration | ≥3 years on therapy | | Molecular depth | DMR at MR4.0 (≤0.01% BCR::ABL1) | | Duration of DMR | ≥2 years, documented on ≥4 tests, 3+ months apart | | Testing access | qPCR with MR4.5 sensitivity, results in ≤2 weeks | | Monitoring commitment | Monthly → bimonthly → quarterly testing indefinitely | | Specialist input | CML specialist consultation required |

---

Important Limitations & Next Steps

What I don't have detailed information on:

• Your specific BCR::ABL1 trajectory and current level
• Your Sokal risk score at diagnosis
• Whether you have any BCR::ABL1 kinase domain mutations
• Your current TKI and how long you've been on it

These are critical factors your CML specialist will evaluate to determine your individual TFR candidacy.

My recommendation: Bring this information to your next appointment and discuss TFR as a potential long-term goal. If your specialist hasn't mentioned it, ask directly. If they're not experienced with TFR management, ask for a referral to a CML specialist center—the NCCN Guidelines specifically recommend this